Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Imfirst: A phase IIIb, safety, single arm study of carboplatin (CB) or cisplatin (CP) plus etoposide (ET) with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in Spain—Primary safety results of the induction phase

Autor: Ruben Alonso, Natalia Fernandez, Gerardo Huidobro Vence, Santiago Ponce Aix, Guillot Mónica, Enric Carcereny, Maria Rosario Garcia Campelo, Manuel Cobo, Emilio Esteban, Margarita Majem, Manuel Domine, Edurne Arriola, Jose Fuentes Pradera, Bartomeu Massuti, Alberto Moreno, Juan Felipe Cordoba, Natalia Lerones, Javier de Castro, Ana Laura Ortega, L. Crama

Publikováno v: Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

8567 Background: Clinical trial (CT) IMpower133 met both primary endpoints and is the first CT to show significant clinical improvement over standard chemotherapy (C) with a good safety profile in first line (1L) ES-SCLC. The addition of ATZ to CB +

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2606371f629917fe5be481088033b85a
https://doi.org/10.1200/jco.2021.39.15_suppl.8567

Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs)

Autor: Beatriz García Paredes, Maria Jose Ortiz, I. Alés, Manuel Valladares-Ayerbes, Enrique Aranda, Javier Sastre, Guillermo Alfonso Quintero Aldana, Juan José Reina-Zoilo, Luis Robles, Eduardo Díaz-Rubio, Adelaida La Casta Munoa, Antonieta Salud Salvia, Pilar García-Alfonso, Jose María Vieitez, Javier Gallego Plazas, Maria Jose Safont, Guillot Mónica, Carlos López-López, Eduardo Polo Marques, Rafael López

Publikováno v: Journal of Clinical Oncology. 37:3549-3549

3549 Background: The outcome for mCRC has changed since the introduction of new chemotherapy schedules and targeted therapies, however new predictive biomarkers are needed. bCTCs and BRAF / PIK3CA mutations have been studied as a potential predictive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6e91a8c79997fe66c7ad506c85b34bf
https://doi.org/10.1200/jco.2019.37.15_suppl.3549

Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL)

Autor: Juan José Reina, Adelaida La Casta Munoa, Guillermo Alfonso Quintero Aldana, Silvia Gil, Encarnación González Flores, Rafael López, Mercedes Salgado Fernández, Pilar Alfonso, Eduardo Díaz-Rubio, A. Gomez, Jose María Vieitez, Ma. José Flor Oncala, Beatriz García-Paredes, Antonieta Salud Salvia, Begoña Graña Suárez, Maria Jose Safont, Guillot Mónica, Mercedes Rodríguez Garrote, Eva Martínez de Castro, Enrique Aranda

Publikováno v: Journal of Clinical Oncology. 36:3536-3536

3536Background: FOLFOXIRI plus bevacizumab has demonstrated a survival benefit compared with FOLFIRI plus bevacizumab (TRIBE Lancet Oncol 2015) in first-line mCRC. This schedule is not routinely re...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::67a5df6fe1731ed401ca8ab2203ed641
https://doi.org/10.1200/jco.2018.36.15_suppl.3536